Abstract
Autoimmunity is an overreaction of immune competent cells to self structures resulting in an unwanted clinical outcome. Traditional therapeutic strategies, still relevant in many cases, involve broad acting immunosuppressants such as cyclophosphamide with the predictable attendant toxicity. More recent concepts include blockade of specifically defined targets such as TNF-α, with resulting immunomodulation and less toxicity. Both of these strategies require ongoing drug treatment of established disease.
A long standing goal, not yet achieved, is the predictable induction of tolerance, obviating the need for chronic treatment. Experimental strategies to achieve this include pre-emptive (preclinical) treatment before chronification is established, total immune ablation and immune “resetting“ and autoantigen immunisation.
Keywords: Autoimmune disease, biologics, stem cell transplantation, autoimmunity, immune competent cells, immunosuppressants, cyclophosphamide, TNF-α, immunomodulation, toxicity.
Current Pharmaceutical Design
Title:Modern Therapeutic Strategies for Autoimmune Diseases
Volume: 18 Issue: 29
Author(s): Alan Tyndall
Affiliation:
Keywords: Autoimmune disease, biologics, stem cell transplantation, autoimmunity, immune competent cells, immunosuppressants, cyclophosphamide, TNF-α, immunomodulation, toxicity.
Abstract: Autoimmunity is an overreaction of immune competent cells to self structures resulting in an unwanted clinical outcome. Traditional therapeutic strategies, still relevant in many cases, involve broad acting immunosuppressants such as cyclophosphamide with the predictable attendant toxicity. More recent concepts include blockade of specifically defined targets such as TNF-α, with resulting immunomodulation and less toxicity. Both of these strategies require ongoing drug treatment of established disease.
A long standing goal, not yet achieved, is the predictable induction of tolerance, obviating the need for chronic treatment. Experimental strategies to achieve this include pre-emptive (preclinical) treatment before chronification is established, total immune ablation and immune “resetting“ and autoantigen immunisation.
Export Options
About this article
Cite this article as:
Tyndall Alan, Modern Therapeutic Strategies for Autoimmune Diseases, Current Pharmaceutical Design 2012; 18 (29) . https://dx.doi.org/10.2174/138161212802502170
DOI https://dx.doi.org/10.2174/138161212802502170 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Glucocorticoids in Breast Cancer
Current Pharmaceutical Design Signaling Pathways Associated with Inflammatory Bowel Disease
Recent Patents on Inflammation & Allergy Drug Discovery Tissular Senescence and Modifications of Oral Ecosystem in the Elderly: Risk Factors for Mucosal Pathologies
Current Aging Science Statins Therapy for Connective Tissue Diseases: New Therapeutic Opportunities
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Mimicry in Autoimmune Neurological Disease after Viral Infection
Current Medicinal Chemistry Identification of Novel Scaffolds for IκB Kinase Beta Inhibitor via a High Throughput Screening TR-FRET Assay
Combinatorial Chemistry & High Throughput Screening The Role of Neutrophil Proteases in LPS-Induced Production of Regulatory Rheumatoid Factor that Suppresses Autoimmunity
Endocrine, Metabolic & Immune Disorders - Drug Targets Use of MHC II Structural Features in the Design of Vaccines for Organ-Specific Autoimmune Diseases
Current Pharmaceutical Design Cot/Tpl-2 Protein Kinase as a Target for the Treatment of Inflammatory Disease
Current Topics in Medicinal Chemistry The Role of Tec Family Kinases in Inflammatory Processes
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Guar Gum and HPMC Coated Colon Targeted Delivery of 6-Mercapto-Purine
The Natural Products Journal Chitosan Nanoparticles: A Therapeutic Carrier for Delivery of DNA, siRNA and CpG-ODNs
Nanoscience & Nanotechnology-Asia Natural Killer T Cells and Autoimmune Disease
Current Molecular Medicine Experimental Models of Relapsing-Remitting Multiple Sclerosis: Current Concepts and Perspective
Current Neurovascular Research Oral Agents in Multiple Sclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Endothelial Effects of Drugs Designed to Treat Erectile Dysfunction
Current Pharmaceutical Design Toll-Like Receptor Signaling Mechanisms Involved in Dendritic Cell Activation: Potential Therapeutic Control of T Cell Polarization
Current Pharmaceutical Design A New Drug Candidate (GEMSP) for Multiple Sclerosis
Current Medicinal Chemistry Targeting Regulatory T Cells in the Treatment of Type 1 Diabetes Mellitus
Current Molecular Medicine Thrombotic Microangiopathies: Towards a Pathophysiology-Based Classification
Cardiovascular & Hematological Disorders-Drug Targets